Thomas Hoenen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals
    Thomas Hoenen
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA Electronic address
    Antiviral Res 99:207-13. 2013
  2. pmc Current ebola vaccines
    Thomas Hoenen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit Laboratory of Virology, 2A120A, 903 S 4th St, Hamilton, MT, USA
    Expert Opin Biol Ther 12:859-72. 2012
  3. pmc Inclusion bodies are a site of ebolavirus replication
    Thomas Hoenen
    Laboratory for Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 86:11779-88. 2012
  4. pmc A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity
    Ari Watt
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    J Virol 88:10511-24. 2014
  5. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012
  6. pmc Development and application of reporter-expressing mononegaviruses: current challenges and perspectives
    Darryl Falzarano
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
    Antiviral Res 103:78-87. 2014
  7. pmc Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure
    Masfique Mehedi
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Pathog 9:e1003677. 2013
  8. doi request reprint Reverse genetics systems as tools for the development of novel therapies against filoviruses
    Thomas Hoenen
    Division of Intramural Research, Laboratory of Virology, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Expert Rev Anti Infect Ther 12:1253-63. 2014
  9. pmc Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA
    Viruses 6:3663-82. 2014
  10. pmc Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes
    Jason Kindrachuk
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA
    J Virol 88:9877-92. 2014

Collaborators

Detail Information

Publications11

  1. pmc A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals
    Thomas Hoenen
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA Electronic address
    Antiviral Res 99:207-13. 2013
    ..The availability of this recombinant virus will allow for more rapid and quantitative evaluation of antivirals against EBOV, as well as the study of details of the EBOV life cycle...
  2. pmc Current ebola vaccines
    Thomas Hoenen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit Laboratory of Virology, 2A120A, 903 S 4th St, Hamilton, MT, USA
    Expert Opin Biol Ther 12:859-72. 2012
    ..However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever...
  3. pmc Inclusion bodies are a site of ebolavirus replication
    Thomas Hoenen
    Laboratory for Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 86:11779-88. 2012
    ..Based on these data we conclude that, rather than being inert aggregates of nucleocapsids, ebolavirus inclusion bodies are in fact complex and dynamic structures and an important site at which viral RNA replication takes place...
  4. pmc A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity
    Ari Watt
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    J Virol 88:10511-24. 2014
    ..Based on our findings, we propose a model for the function of VP24 that reconciles all currently available data regarding the role of VP24 in nucleocapsid assembly as well as genome replication and transcription...
  5. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012
    ..Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence...
  6. pmc Development and application of reporter-expressing mononegaviruses: current challenges and perspectives
    Darryl Falzarano
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
    Antiviral Res 103:78-87. 2014
    ....
  7. pmc Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure
    Masfique Mehedi
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Pathog 9:e1003677. 2013
    ..Overall, our results provide novel insights into the RNA editing mechanism of EBOV, further understanding of which might result in novel intervention strategies against this viral pathogen. ..
  8. doi request reprint Reverse genetics systems as tools for the development of novel therapies against filoviruses
    Thomas Hoenen
    Division of Intramural Research, Laboratory of Virology, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Expert Rev Anti Infect Ther 12:1253-63. 2014
    ..The availability of these reverse genetics-based tools will significantly improve our ability to find novel antivirals against filoviruses. ..
  9. pmc Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA
    Viruses 6:3663-82. 2014
    ....
  10. pmc Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes
    Jason Kindrachuk
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA
    J Virol 88:9877-92. 2014
    ..From these observations, we propose a model for a broader role of TGF-β-mediated signaling responses in the pathogenesis of Ebola virus disease...
  11. pmc Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses
    Thomas Hoenen
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA Department of Virology, Philipps University Marburg, Marburg, Germany
    Antiviral Res 91:195-208. 2011
    ....